BAO PHARMA-B Repurchases 183,400 H-Shares for HKD 2.99 Million, Lifting Treasury Stock to 2.58 Million Shares

Bulletin Express09-04 18:22

Shanghai Bao Pharmaceuticals Co., Ltd. (trading as BAO PHARMA-B) disclosed that it repurchased 183,400 H-shares on the Hong Kong Stock Exchange on 4 September 2026. The on-market transactions were executed at prices ranging from HKD 15.92 to HKD 16.90 per share, translating into a total consideration of HKD 2.99 million and a volume-weighted average cost of HKD 16.32 per share.

Following the buyback, the company’s issued share capital (excluding treasury shares) declined by 0.12% to 151.75 million shares, while treasury shares rose to 2.58 million. The overall number of issued shares remained unchanged at 154.33 million.

The repurchases were made under the general mandate approved by shareholders on 26 May 2026, which authorises the company to buy back up to 15.43 million shares. Cumulative repurchases under this mandate now total 2.58 million shares, representing 1.67% of the issued share count as at the mandate date.

In line with Main Board Rule 10.06(3)(a), BAO PHARMA-B is subject to a moratorium on issuing new shares or disposing of treasury shares until 4 October 2026. The company confirmed that the transactions were carried out in full compliance with Hong Kong Stock Exchange listing rules and all relevant regulatory requirements.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1159388329?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-04 18:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1159388329","market":"us","top_or_hot":-1,"title":"BAO PHARMA-B Repurchases 183,400 H-Shares for HKD 2.99 Million, Lifting Treasury Stock to 2.58 Million Shares","media":"Bulletin Express","content":"<p>Shanghai Bao Pharmaceuticals Co., Ltd. (trading as BAO PHARMA-B) disclosed that it repurchased 183,400 H-shares on the Hong Kong Stock Exchange on 4 September 2026. The on-market transactions were executed at prices ranging from HKD 15.92 to HKD 16.90 per share, translating into a total consideration of HKD 2.99 million and a volume-weighted average cost of HKD 16.32 per share.</p>\n<p>Following the buyback, the company’s issued share capital (excluding treasury shares) declined by 0.12% to 151.75 million shares, while treasury shares rose to 2.58 million. The overall number of issued shares remained unchanged at 154.33 million.</p>\n<p>The repurchases were made under the general mandate approved by shareholders on 26 May 2026, which authorises the company to buy back up to 15.43 million shares. Cumulative repurchases under this mandate now total 2.58 million shares, representing 1.67% of the issued share count as at the mandate date.</p>\n<p>In line with Main Board Rule 10.06(3)(a), BAO PHARMA-B is subject to a moratorium on issuing new shares or disposing of treasury shares until 4 October 2026. The company confirmed that the transactions were carried out in full compliance with Hong Kong Stock Exchange listing rules and all relevant regulatory requirements.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BAO PHARMA-B Repurchases 183,400 H-Shares for HKD 2.99 Million, Lifting Treasury Stock to 2.58 Million Shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBAO PHARMA-B Repurchases 183,400 H-Shares for HKD 2.99 Million, Lifting Treasury Stock to 2.58 Million Shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-09-04 18:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Bao Pharmaceuticals Co., Ltd. (trading as BAO PHARMA-B) disclosed that it repurchased 183,400 H-shares on the Hong Kong Stock Exchange on 4 September 2026. The on-market transactions were executed at prices ranging from HKD 15.92 to HKD 16.90 per share, translating into a total consideration of HKD 2.99 million and a volume-weighted average cost of HKD 16.32 per share.</p>\n<p>Following the buyback, the company’s issued share capital (excluding treasury shares) declined by 0.12% to 151.75 million shares, while treasury shares rose to 2.58 million. The overall number of issued shares remained unchanged at 154.33 million.</p>\n<p>The repurchases were made under the general mandate approved by shareholders on 26 May 2026, which authorises the company to buy back up to 15.43 million shares. Cumulative repurchases under this mandate now total 2.58 million shares, representing 1.67% of the issued share count as at the mandate date.</p>\n<p>In line with Main Board Rule 10.06(3)(a), BAO PHARMA-B is subject to a moratorium on issuing new shares or disposing of treasury shares until 4 October 2026. The company confirmed that the transactions were carried out in full compliance with Hong Kong Stock Exchange listing rules and all relevant regulatory requirements.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02659","symbol_name":"宝济药业-B","start_time":0,"source_url":"","article_id":"1159388329","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1159388329","pubTimestamp":1788517321,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai Bao Pharmaceuticals Co., Ltd. (trading as BAO PHARMA-B) disclosed that it repurchased 183,400 H-shares on the Hong Kong Stock Exchange on 4 September 2026. The on-market transactions were...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02659":"宝济药业-B"},"translate_title":"宝药B以299万港元回购18.34万股H股，库存股增至258万股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02659":1},"content_text":"Shanghai Bao Pharmaceuticals Co., Ltd. (trading as BAO PHARMA-B) disclosed that it repurchased 183,400 H-shares on the Hong Kong Stock Exchange on 4 September 2026. The on-market transactions were executed at prices ranging from HKD 15.92 to HKD 16.90 per share, translating into a total consideration of HKD 2.99 million and a volume-weighted average cost of HKD 16.32 per share.\nFollowing the buyback, the company’s issued share capital (excluding treasury shares) declined by 0.12% to 151.75 million shares, while treasury shares rose to 2.58 million. The overall number of issued shares remained unchanged at 154.33 million.\nThe repurchases were made under the general mandate approved by shareholders on 26 May 2026, which authorises the company to buy back up to 15.43 million shares. Cumulative repurchases under this mandate now total 2.58 million shares, representing 1.67% of the issued share count as at the mandate date.\nIn line with Main Board Rule 10.06(3)(a), BAO PHARMA-B is subject to a moratorium on issuing new shares or disposing of treasury shares until 4 October 2026. The company confirmed that the transactions were carried out in full compliance with Hong Kong Stock Exchange listing rules and all relevant regulatory requirements.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1159388329","isCrawlerRequest":true}